Network Version
GSK269962A Data Sheet
| Product Name: | GSK269962A |
 |
|---|---|---|
| CAS No.: | 850664-21-0 | |
| Cat. No.: | HY-15556 | |
| MWt: | 570.6 | |
| Formula: | C29H30N8O5 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 30 mg/mL;H<sub>2</sub>O : < 0.1 mg/mL | |
| Mechanisms: | Target: Cardiovascular Disease Inflammation/Immunology | |
| Biological Activity: | ||
|
GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities[1].
IC50 & Target: IC50: 1.6 nM (ROCK1), 4 nM (ROCK2)[1]
In Vitro: GSK269962A has an IC50 of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases[1]. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC50 of 35 nM[1]. In Vivo: GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial[1]. |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com